Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Nov-Dec;61(6):362-377.
doi: 10.1016/j.hjc.2020.09.015. Epub 2020 Oct 9.

Cardiovascular disease in women: Executive summary of the expert panel statement of women in cardiology of the hellenic cardiological society

Collaborators, Affiliations
Review

Cardiovascular disease in women: Executive summary of the expert panel statement of women in cardiology of the hellenic cardiological society

Christina Chrysohoou et al. Hellenic J Cardiol. 2020 Nov-Dec.

Abstract

The perception that women represent a low-risk population for cardiovascular (CV) disease (CVD) needs to be reconsidered. Starting from risk factors, women are more likely to be susceptible to unhealthy behaviors and risk factors that have different impact on CV morbidity and mortality as compared to men. Despite the large body of evidence as regards the effect of lifestyle factors on the CVD onset, the gender-specific effect of traditional and non-traditional risk factors on the prognosis of patients with already established CVD has not been well investigated and understood. Furthermore, CVD in women is often misdiagnosed, underestimated, and undertreated. Women also experience hormonal changes from adolescence till elder life that affect CV physiology. Unfortunately, in most of the clinical trials women are underrepresented, leading to the limited knowledge of CV and systemic impact effects of several treatment modalities on women's health. Thus, in this consensus, a group of female cardiologists from the Hellenic Society of Cardiology presents the special features of CVD in women: the different needs in primary and secondary prevention, as well as therapeutic strategies that may be implemented in daily clinical practice to eliminate underestimation and undertreatment of CVD in the female population.

Keywords: Cardiovascular; Heart disease; Primary prevention; Secondary prevention; Women.

PubMed Disclaimer

Figures

Image 1
Graphical abstract

Comment in

  • Women in cardiology.
    Casadei B. Casadei B. Hellenic J Cardiol. 2020 Nov-Dec;61(6):378-379. doi: 10.1016/j.hjc.2021.02.008. Epub 2021 Feb 20. Hellenic J Cardiol. 2020. PMID: 33617962 No abstract available.
  • Invasive therapies in women.
    Sbarouni E. Sbarouni E. Hellenic J Cardiol. 2020 Nov-Dec;61(6):380. doi: 10.1016/j.hjc.2021.02.009. Hellenic J Cardiol. 2020. PMID: 33771327 No abstract available.

References

    1. Mosca L., Benjamin E.J., Berra K. Effectiveness-based guidelines for the prevention of cardiovascular disease in women—2011 update: a guideline from the American Heart Association. Circulation. 2011;123:1243–1262. - PMC - PubMed
    1. Gong I.Y., Tan N.S., Ali S.H. Temporal trends of women enrollment in major cardiovascular randomized clinical trials. Can J Cardiol. 2019;35:653–660. - PubMed
    1. Scott P.E., Unger E.F., Jenkins M.R. Participation of women in clinical trials supporting FDA approval of cardiovascular drugs. J Am Coll Cardiol. 2018;71:1960–1969. - PubMed
    1. Garcia M., Mulvagh S.L., Merz C.N., Buring J.E., Manson J.E. Cardiovascular disease in women: clinical perspectives. Circ Res. 2016;118:1273–1293. - PMC - PubMed
    1. Cho L., Davis M., Elgendy I. Summary of updated recommendations for primary prevention of cardiovascular disease in women. J Am Coll Cardiol. 2020;75:2602–2618. - PMC - PubMed

LinkOut - more resources